

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

**VOLUNTARY ANNOUNCEMENT
PROPOSED SHARE BUY BACK**

This is a voluntary announcement made by PuraPharm Corporation Limited (the “**Company**”).

The board of directors of the Company (the “**Board**”) has been granted a general mandate by the shareholders of the Company (the “**Shareholders**”) to buy back up to 24,771,792 shares of the Company (the “**Shares**”), being 10% of the total number of issued Shares as at the date of the Company’s 2017 annual general meeting held on 26 May 2017 (the “**Share Buy-back Mandate**”).

The Board currently intends to exercise its powers under the Share Buy-back Mandate to buy back Shares (the “**Proposed Share Buy-back**”) in the open market from time-to-time. The Company will conduct the Proposed Share Buy-back in compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

The Proposed Share Buy-back shall not result in the number of the Shares held by the public falling below the minimum public float requirement of 25% as set out under Rules 8.08(1)(a) and 13.32 of the Listing Rules. The Company will subsequently cancel the Shares bought back, if any. The Company will finance the Proposed Share Buy-back with its existing available cash.

The Board considers that the current trading price of the Shares does not reflect their intrinsic value. The Board believes that the Proposed Share Buy-back reflects the Company’s confidence in its long term business prospects and would ultimately benefit the Company and create value for the Shareholders. The Board also believes that the Proposed Share Buy-back is in the interests of the Company and the Shareholders as a whole.

Shareholders and potential investors should note that as at the date of this announcement, the Company has not bought back any Shares. The exercise of the Share Buy-back Mandate by the Company will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance of the time, quantity or price of any buy back of Shares.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 15 February 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, Mr. Chan Lung Sang and Ms. Man Yee Wai, Viola; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.